SCF ENCYCLOPEDIA ENTRY

YELLOW FEVER

I. SCOPE & POSITIONING

Pathogen / Etiology: Yellow fever virus

Classification: Viral (Flaviviridae family; positive-sense single-stranded RNA virus)

Transmission:

• Mosquito-borne:
• Aedes species (urban cycle)
• Haemagogus species (jungle cycle)

Primary Tropism:

• Liver (hepatocytes)
• Endothelial cells
• Kidneys

SCF Classification:

Vector-Borne Hepatotropic Hemorrhagic Necrotizing Viral Systemic Inflammatory Collapse Disorder (VHHNVSICD Class)

II. GLOBAL & CLINICAL SIGNIFICANCE

• Endemic in:
• Sub-Saharan Africa
• South America

Clinical Hallmarks:

• Fever
• Jaundice (“yellow” skin/eyes)
• Bleeding tendencies

Critical Risks:

• Liver failure
• Hemorrhagic shock
• Multi-organ failure

Aligned SCF Clinical Domains:

• C6: Hepatic Systems
• C5: Vascular Systems
• C2: Infectious & Inflammatory Medicine
• C12: Vector-Borne Viral Diseases

III. ETIOPATHOGENIC CORE

Primary Mechanisms:

1. Mosquito inoculation
2. Local replication → viremia
3. Viral spread to liver
4. Hepatocellular damage
5. Systemic inflammatory and hemorrhagic response

Key Drivers:

• Hepatotropism
• Cytokine-mediated inflammation
• Coagulation dysfunction

IV. SCF FAULT ARCHITECTURE

Key Insight:

Yellow fever is a liver-centered systemic collapse disorder, where hepatic failure drives downstream vascular and metabolic breakdown.

V. MULTI-OMICS PATHOGENESIS MAP (Hepatotropic Hemorrhagic Model)

A. Genomics

• RNA genome with virulence variability
• Strain differences affect severity

B. Transcriptomics

• Activation of inflammatory cytokines
• Hepatic stress signaling

C. Proteomics

• Envelope (E) protein:
• Mediates host cell entry
• Nonstructural proteins:
• Suppress immune response

D. Epigenomics

• Immune dysregulation
• Liver injury signaling pathways

E. Metabolomics

• Impaired liver metabolism
• Disrupted detoxification pathways
• Accumulation of toxic metabolites

F. Interactomics

• Virus–hepatocyte interaction
• Immune–vascular interaction

G. Hepatic–Vascular Interface

• Hepatocyte necrosis
• Reduced clotting factor production
• Capillary leakage and bleeding

VI. PATHOGENESIS FLOW (SCF LOGIC)

Mosquito bite → Viremia → Liver infection → Hepatocyte damage → Coagulation failure → Hemorrhage → Organ failure

VII. CLINICAL SPECTRUM

1. INITIAL PHASE

• Fever
• Headache
• Myalgia

2. REMISSION PHASE

• Temporary symptom improvement

3. TOXIC PHASE (SEVERE)

• Jaundice
• Bleeding (gums, GI tract)
• Kidney dysfunction
• Shock

Case Fatality:

• High in severe (toxic) phase

VIII. SCF DISEASE-ORIGIN MODEL

A. Core Mechanisms:

• Hepatic injury
• Coagulation disruption
• Systemic inflammation

B. SCF Classification:

• Primary: Hepatotropic Viral Infection
• Secondary: Hemorrhagic Systemic Collapse Disorder

IX. SCF TRINITY FRAMEWORK MAPPING

Interpretation:

Yellow fever represents a metabolic-collapse cascade, where liver failure leads to systemic breakdown.

X. SCF PCR THERAPEUTIC STRATEGY

1. PREVENTATIVE (P)

• Vaccination (highly effective)
• Mosquito control
• Travel precautions

2. CURATIVE (C)

• No specific antiviral therapy

Supportive Care:

• Fluid management
• Hemodynamic support
• Blood product replacement (if bleeding)

3. RESTORATIVE (R)

• Liver recovery support
• Monitoring organ function
• Long-term follow-up

XI. CURRENT STANDARD OF CARE

• Preventative vaccination
• Supportive ICU care for severe cases

XII. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

High-Value Targets:

• Viral entry into hepatocytes
• Immune-mediated liver damage
• Coagulation pathway disruption

SCF Design Strategy:

• Hepatoprotective antivirals
• Immune-modulating therapies
• Coagulation-stabilizing agents

XIII. RHENOVA INTEGRATION (REDOX–HYPOXIA LOGIC)

Core Disruption:

• Hepatic hypoxia
• Oxidative stress
• Systemic metabolic failure

SCF–RHENOVA Role:

• Monitor liver oxygenation
• Predict systemic collapse
• Guide ICU intervention

XIV. TRANSLATIONAL BLUEPRINT (FDA-ALIGNED)

Preclinical:

• Flavivirus liver models
• Hemorrhagic disease studies

Clinical:

• Vaccine efficacy
• Early detection of severe disease
• Organ support strategies

Biomarkers:

• Elevated liver enzymes (AST, ALT)
• Bilirubin elevation (jaundice)
• Coagulation markers (INR, platelets)

XV. SCF DBI INTERPRETATION

Insight:

Yellow fever represents a DBI hepatic failure cascade model, where liver dysfunction triggers systemic vascular and metabolic collapse.

XVI. SCF LAYMAN’S TRANSLATION SUMMARY

Yellow fever is a mosquito-borne viral disease that affects the liver.

It:

• Causes fever and jaundice
• Can lead to bleeding and organ failure
• Is preventable with a vaccine

SCF treatment focuses on:

• Prevention through vaccination
• Supporting the body during illness
• Managing complications

XVII. MASTER REGISTRY INDEX

• SCF-VIR-YF-0001 — Yellow Fever Entry
• SCF-FLAVIVIRUS-0002 — Viral Module
• SCF-HEPATIC-0003 — Liver Registry
• SCF-RHENOVA-HYPOXIA-0004 — Metabolic Mapping
• SCF-DBI-HEPATIC-0005 — Collapse Model

NEXT STEP OPTIONS

If you want to go deeper, I can generate:

• SCF comparison: Yellow fever vs Dengue vs Ebola (hemorrhagic models)
• API discovery targeting hepatotropic viral replication
• Liver-protective SCF therapeutic platform
• Hemorrhagic fever system modeling (SCF)